Amgen Inc. (AMGN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 25.50B USD | Liabilities, Current |
| Cash and equivalents | 13.99B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 10.23B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 6.22B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $25.50B | $13.99B | (m) | $10.23B | $6.22B | (m) |
| 2026-03-31 | (m) | $24.95B | $12.04B | (m) | $9.14B | $6.19B | (m) |
| 2025-12-31 | (m) | $25.49B | $9.13B | (m) | $9.57B | $6.22B | (m) |
| 2025-09-30 | (m) | $21.79B | $9.45B | (m) | $8.49B | $6.35B | (m) |
| 2025-06-30 | (m) | $20.48B | $8.03B | (m) | $8.70B | $6.58B | (m) |
| 2025-03-31 | (m) | $23.01B | $8.81B | (m) | $8.13B | $6.73B | (m) |
| 2024-12-31 | (m) | $23.10B | $11.97B | (m) | $6.78B | $7.00B | (m) |
| 2024-09-30 | (m) | $20.31B | $9.01B | (m) | $7.32B | $7.36B | (m) |
| 2024-06-30 | (m) | $21.52B | $9.30B | (m) | $6.93B | $8.00B | (m) |
| 2024-03-31 | (m) | $19.71B | $9.71B | (m) | $6.78B | $8.72B | (m) |
| 2023-12-31 | $18.21B | $18.39B | $10.94B | $0.00 | $7.27B | $9.52B | 0.99× |
| 2023-09-30 | $40.89B | $16.95B | $34.74B | $0.00 | $6.14B | $5.03B | 2.41× |
| 2023-06-30 | $40.08B | $17.10B | $34.25B | $0.00 | $5.83B | $4.98B | 2.34× |
| 2023-03-31 | $37.30B | $14.21B | $31.56B | $1.00M | $5.74B | $5.01B | 2.62× |
| 2022-12-31 | $14.87B | $15.69B | $7.63B | $1.68B | $5.56B | $4.93B | 0.95× |
| 2022-09-30 | $16.80B | $14.33B | $9.50B | $1.98B | $5.33B | $4.76B | 1.17× |
| 2022-06-30 | $12.51B | $12.62B | $5.20B | $1.98B | $5.33B | $4.55B | 0.99× |
| 2022-03-31 | $11.62B | $12.89B | $6.53B | $16.00M | $5.08B | $4.41B | 0.90× |
| 2021-12-31 | $12.93B | $12.18B | $7.99B | $48.00M | $4.89B | $4.09B | 1.06× |
| 2021-09-30 | $17.69B | $14.84B | $11.97B | $952.00M | $4.76B | $4.15B | 1.19× |
| 2021-06-30 | $12.56B | $14.59B | $6.63B | $1.45B | $4.48B | $4.12B | 0.86× |
| 2021-03-31 | $14.99B | $12.87B | $6.11B | $4.45B | $4.42B | $4.02B | 1.16× |
| 2020-12-31 | $15.17B | $11.65B | $6.27B | $4.38B | $4.53B | $3.89B | 1.30× |
| 2020-09-30 | $16.45B | $9.95B | $9.09B | $3.27B | $4.09B | $3.94B | 1.65× |
| 2020-06-30 | $16.79B | $10.52B | $9.14B | $2.28B | $5.37B | $3.84B | 1.60× |
| 2020-03-31 | $13.02B | $11.83B | $7.69B | $325.00M | $5.01B | $3.68B | 1.10× |
| 2019-12-31 | $12.97B | $12.84B | $6.04B | $2.87B | $4.06B | $3.58B | 1.01× |
| 2019-09-30 | $24.46B | $10.74B | $11.41B | $9.44B | $3.61B | $3.24B | 2.28× |
| 2019-06-30 | $25.56B | $10.62B | $5.53B | $16.23B | $3.80B | $3.18B | 2.41× |
| 2019-03-31 | $30.07B | $12.71B | $7.36B | $18.94B | $3.77B | $3.02B | 2.37× |
| 2018-12-31 | $32.88B | $13.49B | $6.95B | $22.36B | $3.58B | $2.94B | 2.44× |
| 2018-09-30 | $33.36B | $12.43B | $11.96B | $17.96B | $3.44B | $3.02B | 2.68× |
| 2018-06-30 | $32.90B | $11.21B | $10.13B | $19.26B | $3.50B | $3.06B | 2.94× |
| 2018-03-31 | $35.80B | $10.48B | $9.74B | $22.43B | $3.63B | $2.95B | 3.42× |
| 2017-12-31 | $44.91B | $9.02B | $3.80B | $37.88B | $3.24B | $2.83B | 4.98× |
| 2017-09-30 | $44.76B | $8.19B | $3.00B | $38.35B | $3.40B | $2.93B | 5.46× |
| 2017-06-30 | $42.79B | $7.82B | $2.63B | $36.60B | $3.56B | $2.96B | 5.47× |
| 2017-03-31 | $41.65B | $10.52B | $3.36B | $35.04B | $3.25B | $2.87B | 3.96× |
| 2016-12-31 | $41.25B | $11.20B | $3.24B | $34.84B | $3.17B | $2.75B | 3.68× |
| 2016-09-30 | $41.17B | $10.54B | $3.48B | $34.49B | $3.19B | $2.68B | 3.90× |
| 2016-06-30 | $38.11B | $10.83B | $2.63B | $32.40B | $3.08B | $2.67B | 3.52× |
| 2016-03-31 | $37.82B | $8.52B | $2.90B | $31.84B | $3.08B | $2.57B | 4.44× |
| 2015-12-31 | $34.38B | $8.67B | $4.14B | $27.24B | $3.00B | $2.44B | 3.97× |
| 2015-09-30 | $34.02B | $7.17B | $3.23B | $27.89B | $2.90B | $2.53B | 4.75× |
| 2015-06-30 | $32.77B | $6.89B | $3.79B | $26.20B | $2.78B | $2.57B | 4.76× |
| 2015-03-31 | $29.67B | $6.34B | $2.86B | $24.25B | $2.55B | $2.69B | 4.68× |
| 2014-12-31 | $29.57B | $7.01B | $3.73B | $23.30B | $2.55B | $2.65B | 4.22× |
| 2014-09-30 | $30.43B | $8.55B | $3.68B | $24.40B | $2.35B | $2.88B | 3.56× |
| 2014-06-30 | $28.89B | $7.87B | $4.35B | $21.84B | $2.70B | $2.95B | 3.67× |
| 2014-03-31 | $22.32B | $8.20B | $3.69B | $16.11B | $2.51B | $2.97B | 2.72× |
| 2013-12-31 | $22.10B | $7.95B | $3.81B | $15.60B | $2.70B | $3.02B | 2.78× |
| 2013-09-30 | $25.23B | $4.84B | $8.28B | $14.28B | $2.67B | $2.84B | 5.21× |
| 2013-06-30 | $24.69B | $4.78B | $5.81B | $16.21B | $2.67B | $2.77B | 5.16× |
| 2013-03-31 | $23.80B | $5.14B | $2.53B | $18.74B | $2.53B | $2.74B | 4.63× |
| 2012-12-31 | $26.58B | $8.19B | $3.26B | $20.80B | $2.52B | $2.74B | 3.24× |
| 2012-09-30 | $28.07B | $8.37B | $5.82B | $19.55B | $2.70B | $2.77B | 3.35× |
| 2012-06-30 | $25.18B | $8.03B | $5.85B | $16.63B | $2.71B | $2.59B | 3.14× |
| 2012-03-31 | $22.36B | $8.30B | $4.21B | $15.17B | $2.99B | $2.50B | 2.69× |
| 2011-12-31 | $23.54B | $5.75B | $6.95B | $13.70B | $2.90B | $2.48B | 4.09× |
| 2011-09-30 | $20.40B | $5.32B | $3.89B | $13.79B | $2.73B | $2.36B | 3.84× |
| 2011-06-30 | $21.89B | $4.58B | $6.00B | $13.17B | $2.71B | $2.23B | 4.78× |
| 2011-03-31 | $17.88B | $4.25B | $1.27B | $14.09B | $2.52B | $2.10B | 4.21× |
| 2010-12-31 | $19.76B | $6.57B | $3.29B | $14.13B | $2.33B | $2.02B | 3.01× |
| 2010-09-30 | $19.49B | $6.26B | $2.95B | $14.10B | $2.44B | $2.04B | 3.11× |
| 2010-06-30 | $16.73B | $5.99B | $1.71B | $12.81B | $2.21B | $2.11B | 2.79× |
| 2010-03-31 | $16.39B | $6.56B | $2.27B | $11.85B | $2.27B | $2.20B | 2.50× |
| 2009-12-31 | $15.55B | $3.87B | $2.88B | $10.56B | $2.11B | $2.22B | 4.02× |
| 2009-09-30 | $16.34B | $4.90B | $3.58B | $10.44B | $2.33B | $2.15B | 3.33× |
| 2009-06-30 | $14.15B | $4.55B | $2.97B | $9.00B | $2.18B | $2.06B | 3.11× |
| 2009-03-31 | (m) | (m) | $2.78B | (m) | (m) | (m) | (m) |
| 2008-12-31 | $11.63B | $4.89B | $1.77B | $7.78B | $2.07B | $2.08B | 2.38× |
| 2008-09-30 | (m) | (m) | $2.52B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $3.39B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $2.02B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $1.28B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |